Reference : When and how to stop anti-TNF treatment in inflammatory bowel disease: Predictors of ...
Parts of books : Contribution to collective works
Human health sciences : Gastroenterology & hepatology
When and how to stop anti-TNF treatment in inflammatory bowel disease: Predictors of relapse after stopping treatment
Louis, Edouard mailto [Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie >]
Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
S. Karger AG
[en] anti-TNF ; IBD ; treatment ; predictors ; relapse ; stopping treatment
[en] The global benefit-risk ratio of long-term anti-TNF treatment appears favorable. Nevertheless, reasons exist for contemplating treatment cessation, including patient preference, associated side effects, the development of infection in high-risk patients, pregnancy and cost. Several prospective studies have shown very consistent relapse rates of around 50% at 1 year. Globally, patients with a low risk of relapse are those with steroid-free, clinical, endoscopic and biological remission of Crohn's disease, while no clear predictor has been identified in ulcerative colitis. These studies as well as larger retrospective studies have also shown excellent responses and remission rates and very good tolerabilities of retreatment with the same anti-TNF agents, particularly when patients are concomitantly treated with an immunosuppressant. © 2015 by S. Karger AG. All rights reserved.
Researchers ; Professionals ; Students
© 2017 S. Karger AG, Basel
9783318054743; 9783318054736

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.